Drugs / ZSP1601
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03392779 | Jan → Dec 2018 | metabolic dysfunction-associated steatohepatitis | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT04140123 | Jun 2020 → Aug 2021 | metabolic dysfunction-associated steatohepatitis | Guangdong Raynovent Biotech Co., Ltd | Completed | Met primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05692492 | Jun 2023 → Jun 2026 overdue | metabolic dysfunction-associated steatohepatitis | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-08 | Guangdong Raynovent Biotech Co., Ltd | Results 治疗MASH FIC新药ZSP1601片IIb期临床试验取得积极结果！实现抗纤维化、降脂、降酶三重获益 raynovent.com ↗
近日，广东众生睿创生物科技有限公司宣布，公司自主研发的用于治疗代谢功能障碍相关脂肪性肝炎（MASH）的Ⅰ类创新药ZSP1601片IIb期临床试验顶线数据初步分析结果积极，有力支持继续开展III期临床试验。 |
| 2019-07-02 | Guangdong Raynovent Biotech Co., Ltd | Regulatory 众生睿创获得日本专利证书 raynovent.com ↗
近日，公司收到日本特许厅（Japan Patent Office）颁发的专利证书。 |
| 2019-06-25 | Guangdong Raynovent Biotech Co., Ltd | Regulatory 众生睿创治疗 NASH 一类创新药 ZSP1601 片 获得 Ib/IIa 期临床试验伦理批件 raynovent.com ↗
近日，广东众生睿创生物科技有限公司（以下简称“公司”）用于治疗非酒精性脂肪性肝炎（NASH）的一类创新药物 ZSP1601 片获得组长单位吉林大学第一医院 Ib/IIa 期临床试验伦理批件，临床研究负责人为牛俊奇教授和丁艳华教授。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-08 | Guangdong Raynovent Biotech Co., Ltd | 治疗MASH FIC新药ZSP1601片IIb期临床试验取得积极结果！实现抗纤维化、降脂、降酶三重获益 raynovent.com ↗ |
| 2019-07-02 | Guangdong Raynovent Biotech Co., Ltd | 众生睿创获得日本专利证书 raynovent.com ↗ |
| 2019-06-25 | Guangdong Raynovent Biotech Co., Ltd | 众生睿创治疗 NASH 一类创新药 ZSP1601 片 获得 Ib/IIa 期临床试验伦理批件 raynovent.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSP1601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04140123 ↗ |
| Action | Inhibit | “ZSP1601, a first-in-class pan-phosphodiesterase (PDE) inhibitor” PMID 33682556 ↗ Mar 2021 |
| Route | Oral | “ZSP1601 tablet administered orally once daily under fasted condition” NCT03392779 ↗ |